PeppiLibrary

Skin & Anti-aging

SNAP-8 peptide reference

Topical octapeptide extending the Argireline mechanism. Marketed for stronger expression-line effects.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing SNAP-8 notes
Default dose labelNot listed
Preferred routeTopical
Frequency label2× daily
Storage windowNot listed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
Cosmetic ingredient with limited independent peer-reviewed studies

FDA-approved cosmetic ingredient

Route map

How records are usually labeled

1 Topical

Apply to specific expression-line areas.

Vial timeline

Storage cues to log

Before mixPer product label.
After mixN/A
Use-by cueShelf life not listed
Mixed vial windowNot listed
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial label
Dose Not listed
Route Topical
Review storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for SNAP-8. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

SNAP-8 is a synthetic 8-amino-acid peptide extending the Argireline (acetyl hexapeptide) mechanism. It targets the same SNARE complex destabilisation, with a longer sequence reportedly providing more sustained expression-line softening. Used in cosmetic formulations as a complement to or upgrade from Argireline.

Also known as: Acetyl Octapeptide-3.

Reduction of expression-line depthAnti-aging skincare adjunct

Mechanism and timing snapshot

Mimics the N-terminal sequence of SNAP-25, destabilising the SNARE complex and reducing acetylcholine release at neuromuscular junctions. Reportedly more potent than the parent Argireline.

Onset labelNot listed
Catalog onset field, when available.
Half-life labelNot listed
Topical formulation; locally active
Duration label24 hr
Catalog duration field, when available.
topical Low penetration (~10–20%), comparable to Argireline

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default doseNot listed
Catalog dose rangeNot listed - Not listed
Default routeTopical
Frequency label2× daily
Best time labelMorning under sunscreen, evening as last skincare step.
Food noteN/A — topical.

Catalog protocol note

5–10% concentration cream applied AM and PM to expression-line areas. 4–8 weeks before judging.

Routes and site notes

Available route labelsTopical
Preferred route labelTopical
Common site labelsForehead, Crow's feet, Glabellar lines
Site rotation noteApply to specific expression-line areas.

Chemistry

SequenceAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2
Amino acids8
Molecular formulaC40H67N15O17S
Molecular weight1090.13 Da

Vial, reconstitution, and storage

Supply formPre-formulated cream or serum
Typical vial sizeNot listed
DiluentN/A
Diluent volumeNot listed
Concentration note5–10% concentration is the research-supported range.
Before reconstitutionPer product label.
After reconstitutionN/A
Reconstituted shelf lifeNot listed
Light sensitiveNo
Freeze/thaw warningNo

Safety notes

Common and rare side effects listed in the catalog

  • Generally well-tolerated topically
  • Mild irritation (formulation-dependent)

Contraindications and warnings

  • Open wounds in application area
  • Effects are subtle — not equivalent to injectable Botox.

Other considerations

  • Often paired with Argireline for compounded effect.
  • Consistent twice-daily use over 8+ weeks is required.

Evidence and regulatory context

Evidence levelCosmetic ingredient with limited independent peer-reviewed studies
FDA approvedYes
Regulatory statusFDA-approved cosmetic ingredient
Prescription requiredNo
Approved countriesUS, EU, and most others

Stacking and cycle notes

Stacks well withargireline, matrixyl, ghk-cu
Avoid combining noteNot listed
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceContinuous use; effects regress on discontinuation.

Tracking tips

  • Stacks well with Argireline, Matrixyl, and GHK-Cu in layered routines.
  • Look for 5–10% concentration in well-formulated bases.
  • Allow 8+ weeks before judging — like Argireline, results are gradual.

References

Track it in Peppi

Keep SNAP-8 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for SNAP-8?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use SNAP-8?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export SNAP-8 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026